Protease inhibitors as anticarcinogens.
D000284:Administration, Oral; D000818:Animals; D002273:Carcinogens / Q000037:antagonists & inhibitors; D005609:Free Radicals; D006801:Humans; D051379:Mice; D009369:Neoplasms / Q000139:chemically induced / Q000517:prevention & control*; D009381:Neoplasms, Radiation-Induced / Q000517:prevention & control; D009747:Nutritional Physiological Phenomena; D010960:Plasminogen Activators / Q000627:therapeutic use; D011480:Protease Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D014106:Tosylarginine Methyl Ester / Q000627:therapeutic use
D002273:Carcinogens; D005609:Free Radicals; D011480:Protease Inhibitors; D014106:Tosylarginine Methyl Ester; D010960:Plasminogen Activators